Antibody titres at diagnosis and during follow-up of ant retrospective study

Lancet Neurology, The 13, 167-177

DOI: 10.1016/s1474-4422(13)70282-5

Citation Report

#	Article	IF	CITATIONS
1	Four-Year Course of Serum and Cerebrospinal Fluid Antibody Titers in a Patient with Anti-NMDAR Encephalitis. Journal of Genetic Syndromes & Gene Therapy, 2014, 05, .	0.2	2
2	NMDA receptor antibodies associated with distinct white matter syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e2.	3.1	85
3	Limbic encephalitis with mGluR5 antibodies and immunotherapy-responsive prosopagnosia. Neurology, 2014, 83, 1384-1386.	1.5	44
4	Prevalence of <i>N &lt; /i&gt;-Methyl-D-Aspartate Receptor Autoantibodies in the Peripheral Blood. JAMA Psychiatry, 2014, 71, 838.</i>	6.0	73
5	Relapsing Anti-NMDAR Encephalitis after a gap of eight years in a girl from North-East India. Annals of Indian Academy of Neurology, 2014, 17, 349.	0.2	1
6	Seizures as first symptom of anti-NMDA receptor encephalitis are more common in men. Neurology, 2014, 82, 550-551.	1.5	40
7	Neuronal Surface Antibody-Mediated Autoimmune Encephalitis. Seminars in Neurology, 2014, 34, 458-466.	0.5	57
8	White matter changes in childhood NMDA receptor encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e3.	3.1	3
11	Antibodies to NMDA receptor, bloodâ€"brain barrier disruption and schizophrenia: a theory with unproven links. Molecular Psychiatry, 2014, 19, 1054-1054.	4.1	52
12	Congress report of the 2014 American Academy of Neurology annual meeting. Clinical and Experimental Neuroimmunology, 2014, 5, 391-399.	0.5	1
13	Demyelinating disease and anti-N-methyl-D-aspartate receptor immunoglobulin G antibodies: a case report. BMC Research Notes, 2014, 7, 948.	0.6	14
14	Ovarian teratoma-associated anti-NMDAR encephalitis: a systematic review of reported cases. Orphanet Journal of Rare Diseases, 2014, 9, 157.	1.2	57
15	Autoimmune encephalitis as differential diagnosis of infectious encephalitis. Current Opinion in Neurology, 2014, 27, 361-368.	1.8	148
16	Pediatric inflammatory brain diseases. Current Opinion in Rheumatology, 2014, 26, 553-561.	2.0	30
17	Antibody-mediated central nervous system diseases: disease recognition and treatment challenges. Clinical and Experimental Immunology, 2014, 178, 30-32.	1.1	3
18	Abnormal Neurons in Teratomas in NMDAR Encephalitis. JAMA Neurology, 2014, 71, 717.	4.5	78
19	Overlapping demyelinating syndromes and anti–Nâ€methylâ€Dâ€aspartate receptor encephalitis. Annals of Neurology, 2014, 75, 411-428.	2.8	405
20	Seroprevalence of autoantibodies against brain antigens in health and disease. Annals of Neurology, 2014, 76, 82-94.	2.8	301

#	Article	IF	CITATIONS
21	Reply. Annals of Neurology, 2014, 76, 464-465.	2.8	0
22	Autoimmune encephalitis update. Neuro-Oncology, 2014, 16, 771-778.	0.6	162
23	DPPX potassium channel antibody. Neurology, 2014, 83, 1797-1803.	1.5	255
24	Pediatric Acute-Onset Neuropsychiatric Syndrome. Psychiatric Clinics of North America, 2014, 37, 353-374.	0.7	55
25	Focal Epilepsies: Immunologic and Inflammatory Mechanisms. Seminars in Pediatric Neurology, 2014, 21, 207-213.	1.0	16
27	Cellâ€surface central nervous system autoantibodies: Clinical relevance and emerging paradigms. Annals of Neurology, 2014, 76, 168-184.	2.8	159
28	Autoimmune Movement Disorders in Children: Clinical Characteristics and Therapeutic Considerations. Journal of Pediatric Neurology, 2015, 13, 144-154.	0.0	0
29	Anti-NMDA Receptor Encephalitis in the Polar Bear (Ursus maritimus) Knut. Scientific Reports, 2015, 5, 12805.	1.6	37
30	First Bahraini adolescent with anti-NMDAR-Ab encephalitis. Qatar Medical Journal, 2015, 2015, 2.	0.2	5
31	Transient anti-NMDAR encephalitis in a newborn infant due to transplacental transmission. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e126.	3.1	23
34	Pathologically confirmed autoimmune encephalitis in suspected Creutzfeldt-Jakob disease. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e178.	3.1	47
35	Gilles de la Tourette syndrome is not linked to contactin-associated protein receptor 2 antibodies. Molecular Brain, 2015, 8, 62.	1.3	10
36	Early recognition of antiâ€∢i>Nà€methylâ€Dâ€aspartate receptor encephalitis in psychiatric patients. Acta Psychiatrica Scandinavica, 2015, 132, 312-313.	2.2	3
37	Acute psychosis due to non-paraneoplastic anti-NMDA-receptor encephalitis in a teenage girl: Case report. PsyCh Journal, 2015, 4, 226-230.	0.5	14
38	What Elements of the Inflammatory System Are Necessary for Epileptogenesis <i>In Vitro</i> ?. ENeuro, 2015, 2, ENEURO.0027-14.2015.	0.9	10
39	Update on neurological paraneoplastic syndromes. Current Opinion in Oncology, 2015, 27, 489-495.	1.1	192
40	Heterogeneity of clinical features and corresponding antibodies in seven patients with anti-NMDA receptor encephalitis. Experimental and Therapeutic Medicine, 2015, 10, 1283-1292.	0.8	18
41	Paraneoplastic Disorders. CONTINUUM Lifelong Learning in Neurology, 2015, 21, 452-475.	0.4	22

#	Article	IF	CITATIONS
42	A field guide to current advances in paediatric movement disorders. Current Opinion in Neurology, 2015, 28, 437-446.	1.8	10
43	Specific Roles of NMDA Receptor Subunits in Mental Disorders. Current Molecular Medicine, 2015, 15, 193-205.	0.6	34
44	Anti-N-methyl-d-aspartate receptor encephalitis in a patient with a 7-year history of being diagnosed as schizophrenia: complexities in diagnosis and treatment. Neuropsychiatric Disease and Treatment, 2015, 11, 1437.	1.0	18
45	Neuroimmunology: An Expanding Frontier in Autoimmunity. Frontiers in Immunology, 2015, 6, 206.	2.2	59
46	Anti-NMDA Receptor Encephalitis in a Patient with Previous Psychosis and Neurological Abnormalities: A Diagnostic Challenge. Case Reports in Psychiatry, 2015, 2015, 1-4.	0.2	9
48	Autoimmune Encephalitis., 2015, , 247-276.		O
49	Investigations on CXCL13 in Anti– <i>N</i> -Methyl- <scp>D</scp> -Aspartate Receptor Encephalitis. JAMA Neurology, 2015, 72, 180.	4.5	142
50	Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases. Experimental Neurology, 2015, 270, 66-71.	2.0	54
51	Bipolar disorder and antibodies against the N-methyl-d-aspartate receptor: A gate to the involvement of autoimmunity in the pathophysiology of bipolar illness. Neuroscience and Biobehavioral Reviews, 2015, 55, 403-412.	2.9	24
52	Antibody-Mediated Encephalitis. , 2015, , 177-181.		O
53	No evidence for the presence of neuronal surface autoantibodies in plasma of patients with schizophrenia. European Neuropsychopharmacology, 2015, 25, 2326-2332.	0.3	7
54	CSF IgA NMDAR antibodies are potential biomarkers for teratomas in anti-NMDAR encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e166.	3.1	18
55	Antibodies to Surface Dopamine-2 Receptor and N-Methyl-D-Aspartate Receptor in the First Episode of Acute Psychosis in Children. Biological Psychiatry, 2015, 77, 537-547.	0.7	87
56	Cerebrospinal Fluid in Clinical Neurology. , 2015, , .		16
57	Recognition and Treatment of Anti-N-Methyl-d-Aspartate Receptor Encephalitis. Clinical Pediatric Emergency Medicine, 2015, 16, 3-10.	0.4	2
58	Recent Developments in Paraneoplastic Disorders of the Nervous System. Surgical Pathology Clinics, 2015, 8, 89-99.	0.7	1
59	N-Methyl-d-aspartate receptor autoantibodies in schizophrenia and affective disorders. Schizophrenia Research, 2015, 162, 291.	1.1	6
60	Prevalence of serum <i>N</i> -methyl-d-aspartate receptor autoantibodies in refractory psychosis. British Journal of Psychiatry, 2015, 206, 164-165.	1.7	25

#	ARTICLE	IF	CITATIONS
61	Clinical relevance of serum antibodies to extracellular <i>N</i> -methyl-d-aspartate receptor epitopes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 708-713.	0.9	97
62	Immunoglobulin <scp>G</scp> antibodies to the <scp>N</scp> â€Methylâ€ <scp>D</scp> â€espartate receptor are distinct from immunoglobulin <scp>A</scp> and immunoglobulin <scp>M</scp> responses. Annals of Neurology, 2015, 77, 183-183.	2.8	20
63	Rehabilitation following anti-NMDA encephalitis. Brain Injury, 2015, 29, 785-788.	0.6	10
64	Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e130.	3.1	96
65	CSF findings in patients with anti-N-methyl-d-aspartate receptor-encephalitis. Seizure: the Journal of the British Epilepsy Association, 2015, 29, 137-142.	0.9	75
66	Psychiatric Autoimmunity: N-Methyl-d-Aspartate Receptor IgG and Beyond. Psychosomatics, 2015, 56, 227-241.	2.5	44
67	Neuropsychiatric Symptoms of Inflammatory Demyelinating Diseases. Neuropsychiatric Symptoms of Neurological Disease, $2015, \ldots$	0.3	3
68	Autoimmune Encephalitis in Postpartum Psychosis. American Journal of Psychiatry, 2015, 172, 901-908.	4.0	88
69	Extreme delta brush guides to the diagnosis of anti-NMDAR encephalitis. Journal of the Neurological Sciences, 2015, 353, 81-83.	0.3	27
70	Autoimmune Encephalopathies. Pediatric Clinics of North America, 2015, 62, 667-685.	0.9	27
71	Autoimmune channelopathies in paraneoplastic neurological syndromes. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2665-2676.	1.4	25
72	Fifteen-minute consultation: autoimmune encephalitis. Archives of Disease in Childhood: Education and Practice Edition, 2015, 100, 282-287.	0.3	3
73	Absence of $\langle i \rangle N \langle i \rangle$ -Methyl- $\langle sub \rangle \langle scp \rangle D \langle scp \rangle \langle sub \rangle$ -Aspartate Receptor IgG Autoantibodies in Schizophrenia. JAMA Psychiatry, 2015, 72, 731.	6.0	58
74	Infectious and Autoantibody-Associated Encephalitis: Clinical Features and Long-term Outcome. Pediatrics, 2015, 135, e974-e984.	1.0	115
75	A Confused Child. Clinical Pediatric Emergency Medicine, 2015, 16, 69-74.	0.4	0
76	Rasmussen Syndrome and Other Inflammatory Epilepsies. Seminars in Neurology, 2015, 35, 259-268.	0.5	17
77	Cardiac sympathetic dysfunction in anti-NMDA receptor encephalitis. Autonomic Neuroscience: Basic and Clinical, 2015, 193, 142-146.	1.4	17
78	Autoimmune post–herpes simplex encephalitis of adults and teenagers. Neurology, 2015, 85, 1736-1743.	1.5	226

#	Article	IF	CITATIONS
79	The growing spectrum of antibody-associated inflammatory brain diseases in children. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e92.	3.1	30
80	Anti-NMDAR Encephalitis of 11 Cases in China - Detailed Clinical, Laboratory and Imagiological Description. European Neurology, 2015, 74, 73-78.	0.6	6
81	NMDA receptor antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e141.	3.1	44
82	Psychiatric Presentation of Brain Inflammation. Neuropsychiatric Symptoms of Neurological Disease, 2015, , 87-94.	0.3	0
83	Prognosis of Neurological Diseases. , 2015, , .		1
84	When a serum test overrides the clinical assessment. Neurology, 2015, 84, 1379-1381.	1.5	32
85	Intrathecal treatment of antiâ€ <i>N</i> à€Methylâ€ <scp>d</scp> â€aspartate receptor encephalitis in children. Developmental Medicine and Child Neurology, 2015, 57, 95-99.	1.1	48
86	Autoimmune encephalopathies. Annals of the New York Academy of Sciences, 2015, 1338, 94-114.	1.8	322
87	Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain, 2015, 138, 94-109.	3.7	391
88	Autoimmune NMDA receptor encephalitis. Clinica Chimica Acta, 2015, 438, 90-97.	0.5	34
89	Autoantibodies in Neuropsychiatric Disorders. Antibodies, 2016, 5, 9.	1.2	22
90	The role of NMDAR antibody in the etiopathogenesis of schizophrenia. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 2327-2332.	1.0	11
91	The Laboratory Diagnosis of Autoimmune Encephalitis. Journal of Epilepsy Research, 2016, 6, 45-50.	0.1	90
92			

#	ARTICLE	IF	CITATIONS
97	Psychosis Secondary to Anti-N-methyl-D-Aspartate Receptor Encephalitis. Harvard Review of Psychiatry, 2016, 24, 229-237.	0.9	5
98	Limbic Encephalitis Associated With GAD65 Antibodies: Brief Review of the Relevant literature. Canadian Journal of Neurological Sciences, 2016, 43, 486-493.	0.3	42
99	Systemic Inflammatory Response Syndrome Associated With Clozapine and Successful Rechallenge. Journal of Clinical Psychopharmacology, 2016, 36, 93-95.	0.7	3
100	Anti-Inflammatory Therapy and Immunotherapy Were Partially Effective in a Patient With Anti–N-Methyl-D-Aspartate Receptor Antibodies and a Special Subgroup of Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology, 2016, 36, 92-93.	0.7	10
101	Psychosis: call a surgeon? A rare etiology of psychosis requiring resection. SAGE Open Medical Case Reports, 2016, 4, 2050313X1667008.	0.2	3
102	NMDA receptor encephalitis and other antibody-mediated disorders of the synapse. Neurology, 2016, 87, 2471-2482.	1.5	178
103	Scratching Below the Surface. New England Journal of Medicine, 2016, 375, 2188-2193.	13.9	1
104	Anti-NMDA Receptor Encephalitis, Autoimmunity, and Psychosis. Focus (American Psychiatric) Tj ETQq1 1 0.7843	14 rgBT /0.4	Dvgrlock 10
107	Anti-N-methyl-d-aspartate receptor encephalitis with lung adenocarcinoma. Neurological Sciences, 2016, 37, 1573-1575.	0.9	9
108	Prevalence of antineuronal antibodies in patients with encephalopathy of unknown etiology: Data from a nationwide registry in Korea. Journal of Neuroimmunology, 2016, 293, 34-38.	1.1	13
109	Autoimmunity, neuroinflammation, pathogen load: A decisive crosstalk in neuropsychiatric SLE. Journal of Autoimmunity, 2016, 74, 13-26.	3.0	28
110	Antibody-Mediated Autoimmune Encephalitis in Childhood. Pediatric Neurology, 2016, 60, 13-23.	1.0	63
111	NMDA Receptor Internalization by Autoantibodies: A Reversible Mechanism Underlying Psychosis?. Trends in Neurosciences, 2016, 39, 300-310.	4.2	73
112	Autoimmune movement disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 301-315.	1.0	14
113	The Association Between Atrophy and the Prognosis of Anti- <i>N</i> -Methyl- <scp>d</scp> -Aspartate Receptor Encephalitis. JAMA Neurology, 2016, 73, 643.	4.5	3
114	Cellular, synaptic, and circuit effects of antibodies in autoimmune CNS synaptopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 77-93.	1.0	9
115	Detection methods for neural autoantibodies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 147-163.	1.0	26
116	Anti-NMDAR encephalitis and other glutamate and GABA receptor antibody encephalopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 199-217.	1.0	13

#	Article	IF	CITATIONS
117	Autoimmune dementia and encephalopathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 247-267.	1.0	16
118	Autoimmune neurologic disorders in children. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 485-510.	1.0	9
119	Anti N-methyl-D-aspartate receptor encephalitis: a game-changer?. Expert Review of Neurotherapeutics, 2016, 16, 849-859.	1.4	5
120	Diagnostic and therapeutic strategies for management of autoimmune encephalopathies. Expert Review of Neurotherapeutics, 2016, 16, 937-949.	1.4	29
121	Expanding the Range of Diagnosable Autoimmune Encephalopathies and Encephalomyelopathies. JAMA Neurology, 2016, 73, 1279.	4.5	0
122	Anti-LGI1 encephalitis. Neurology, 2016, 87, 1449-1456.	1.5	455
123	Immunoadsorption or plasma exchange in the treatment of autoimmune encephalitis: a pilot study. Journal of Neurology, 2016, 263, 2395-2402.	1.8	64
125	Anti-LGI1–associated cognitive impairment. Neurology, 2016, 87, 759-765.	1.5	264
126	Altered paired associative stimulationâ€induced plasticity in NMDAR encephalitis. Annals of Clinical and Translational Neurology, 2016, 3, 101-113.	1.7	12
127	The brain as immunoprecipitator of serum autoantibodies against Nâ€Methylâ€Dâ€aspartate receptor subunit NR1. Annals of Neurology, 2016, 79, 144-151.	2.8	<b>7</b> 5
128	Autoimmune encephalitis. Internal Medicine Journal, 2016, 46, 148-157.	0.5	65
129	Current trends in autoimmunity and the nervous system. Journal of Autoimmunity, 2016, 75, 20-29.	3.0	31
130	Human cerebrospinal fluid monoclonal <i>N</i> methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. Brain, 2016, 139, 2641-2652.	3.7	223
131	Autoantibody-Associated Central Nervous System Neurologic Disorders. Seminars in Neurology, 2016, 36, 382-396.	0.5	27
132	Antibody-associated epilepsies: Clinical features, evidence for immunotherapies and future research questions. Seizure: the Journal of the British Epilepsy Association, 2016, 41, 26-41.	0.9	43
133	Prevalence of elevated serum anti-N-methyl-D-aspartate receptor antibody titers in patients presenting exclusively with psychiatric symptoms: a comparative follow-up study. BMC Psychiatry, 2016, 16, 226.	1.1	18
134	Ephrinâ€B2 prevents Nâ€methylâ€Dâ€aspartate receptor antibody effects on memory and neuroplasticity. Annals of Neurology, 2016, 80, 388-400.	2.8	134
136	Neuronal surface antibodies in HIV-infected patients with isolated psychosis. Journal of Neuroimmunology, 2016, 301, 49-52.	1.1	4

#	ARTICLE	IF	CITATIONS
138	Neuronal central nervous system syndromes probably mediated by autoantibodies. European Journal of Neuroscience, 2016, 43, 1535-1552.	1.2	21
139	Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict longâ€term outcome in patients with autoimmune encephalitis. European Journal of Neurology, 2016, 23, 796-806.	1.7	46
140	Status epilepticus and anti-NMDA receptor encephalitis after resection of an ovarian teratoma. Journal of the Intensive Care Society, 2016, 17, 346-352.	1.1	3
141	Clinical utility of testing AQP4-lgG in CSF. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e231.	3.1	113
142	CSF diagnostics in psychiatry – present status – future projects. Neurology Psychiatry and Brain Research, 2016, 22, 69-74.	2.0	17
143	Antibodies in acquired demyelinating disorders in children. Multiple Sclerosis and Demyelinating Disorders, 2016, $1,\ldots$	1.1	4
145	Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. Schizophrenia Research, 2016, 176, 36-40.	1.1	163
146	Childhood Anti-NMDA Receptor Encephalitis. Indian Journal of Pediatrics, 2016, 83, 628-633.	0.3	24
147	Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Review and Neuropsychological Case Study. Clinical Neuropsychologist, 2016, 30, 150-163.	1.5	18
148	Practice Current: How do you treat anti-NMDA receptor encephalitis?. Neurology: Clinical Practice, 2016, 6, 69-72.	0.8	17
149	Anti-NMDAR antibodies in new-onset psychosis. Positive results in an HIV-infected patient. Brain, Behavior, and Immunity, 2016, 56, 56-60.	2.0	22
150	Metabotropic glutamate receptor type 1 autoimmunity. Neurology, 2016, 86, 1009-1013.	1.5	76
151	A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology, The, 2016, 15, 391-404.	4.9	2,782
152	Clinical Features, Therapeutic Response, and Follow-Up in Pediatric Anti-N-Methyl-d-Aspartate Receptor Encephalitis: Experience from a Tertiary Care University Hospital in India. Neuropediatrics, 2016, 47, 024-032.	0.3	26
153	Intrathecal-specific glutamic acid decarboxylase antibodies at low titers in autoimmune neurological disorders. Journal of Neuroimmunology, 2016, 290, 15-21.	1.1	15
154	Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies. Neurotherapeutics, 2016, 13, 147-162.	2.1	78
155	Reply to: N-Methyl-D-Aspartate Receptor Autoantibodies in Psychiatric Illness. Biological Psychiatry, 2016, 79, e63.	0.7	1
156	Autoimmune Encephalitis in the ICU: Analysis of Phenotypes, Serologic Findings, and Outcomes. Neurocritical Care, 2016, 24, 240-250.	1.2	60

#	Article	IF	CITATIONS
157	HSV encephalitis-induced anti-NMDAR encephalitis in a 67-year-old woman: report of a case and review of the literature. Journal of NeuroVirology, 2016, 22, 33-37.	1.0	28
158	Seronegative Anti–N-Methyl-D-Aspartate Receptor Encephalitis. Biological Psychiatry, 2016, 79, e67-e68.	0.7	6
159	Catatonia and Autoimmune Conditions in Children and Adolescents: Should We Consider a Therapeutic Challenge?. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 167-176.	0.7	15
160	Neuropsychological characterization of three adolescent females with anti-NMDA receptor encephalitis in the acute, post-acute, and chronic phases: an inter-institutional case series. Clinical Neuropsychologist, 2017, 31, 268-288.	1.5	22
161	Clinical characteristics, treatments, and outcomes of patients with anti- N -methyl- d -aspartate receptor encephalitis: A systematic review of reported cases. Epilepsy and Behavior, 2017, 68, 57-65.	0.9	61
162	Raised cerebrospinal fluid BAFF and APRIL levels in anti- N -methyl- d -aspartate receptor encephalitis: Correlation with clinical outcome. Journal of Neuroimmunology, 2017, 305, 84-91.	1.1	13
163	Autoimmune Movement Disorders: a Clinical and Laboratory Approach. Current Neurology and Neuroscience Reports, 2017, 17, 4.	2.0	25
164	Anti-NMDA Receptor Antibody Positivity and Presentations Without Seizure, Involuntary Movement, Hypoventilation, or Tumor: A Systematic Review of the Literature. Journal of Neuropsychiatry and Clinical Neurosciences, 2017, 29, 267-274.	0.9	12
165	Autoimmune antibody-associated encephalopathy and dementia syndromes., 0,, 365-399.		0
166	Serum neuronal cell-surface antibodies in first-episode psychosis. Lancet Psychiatry, the, 2017, 4, 186-187.	3.7	6
167	Serum neuronal cell-surface antibodies in first-episode psychosis–Authors' reply. Lancet Psychiatry,the, 2017, 4, 187-188.	3.7	5
168	Autoimmune Encephalopathy for Psychiatrists: When to Suspect Autoimmunity and What to Do Next. Psychosomatics, 2017, 58, 228-244.	2.5	44
169	Autoimmune Encephalitis: Pathophysiology and Imaging Review of an Overlooked Diagnosis. American Journal of Neuroradiology, 2017, 38, 1070-1078.	1.2	214
170	Survey of the diagnostic and therapeutic approach to new-onset refractory status epilepticus. Seizure: the Journal of the British Epilepsy Association, 2017, 46, 24-30.	0.9	25
171	Detection of LGI1 and CASPR2 antibodies with a commercial cell-based assay in patients with very high VGKC-complex antibody levels. Journal of the Neurological Sciences, 2017, 378, 85-90.	0.3	1
172	Detecting synaptic autoantibodies in psychoses: need for more sensitive methods. Current Opinion in Neurology, 2017, 30, 317-326.	1.8	3
173	Persistence of anti-NMDAR antibodies in CSF after recovery from autoimmune encephalitis. Neurological Sciences, 2017, 38, 1523-1524.	0.9	8
174	Lower dosages of rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour. Journal of the Neurological Sciences, 2017, 377, 127-132.	0.3	23

#	Article	IF	Citations
175	Seroprevalence survey of selective anti-neuronal autoantibodies in patients with first-episode schizophrenia and chronic schizophrenia. Schizophrenia Research, 2017, 190, 28-31.	1.1	29
176	Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiological Reviews, 2017, 97, 839-887.	13.1	428
177	Infectious encephalitis: Management without etiological diagnosis 48 hours after onset. Médecine Et Maladies Infectieuses, 2017, 47, 236-251.	5.1	17
178	Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology, 2017, 88, 366-370.	1.5	162
179	Anti-NMDA-Receptor Encephalitis: From Bench to Clinic. ACS Chemical Neuroscience, 2017, 8, 2586-2595.	1.7	37
181	Detection of NMDARs Antibodies in Encephalitis. Methods in Molecular Biology, 2017, 1677, 117-126.	0.4	5
182	Suicidality is a common and serious feature of anti-N-methyl-D-aspartate receptor encephalitis. Journal of Neurology, 2017, 264, 2378-2386.	1.8	13
183	Cerebrospinal fluid analysis and the determination of oligoclonal bands. Neurological Sciences, 2017, 38, 217-224.	0.9	30
184	Improving the antibody-based evaluation of autoimmune encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e404.	3.1	70
185	Diagnostics of autoimmune encephalitis associated with antibodies against neuronal surface antigens. Neurological Sciences, 2017, 38, 225-229.	0.9	17
186	NMDA receptor antibody encephalitis presenting with enhancing lesion and seizures. Neurology: Clinical Practice, 2017, 7, 433-435.	0.8	1
187	Immunoadsorption for autoimmune encephalitis. Atherosclerosis Supplements, 2017, 30, 257-263.	1.2	19
188	Persistence of parenchymal and perivascular T-cells in treatment-refractory anti-N-methyl-D-aspartate receptor encephalitis. NeuroReport, 2017, 28, 890-895.	0.6	5
189	Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients. Nature Communications, 2017, 8, 1791.	5.8	103
190	Anti-NMDA Receptor Antibody Encephalitis. , 2017, , 75-82.		0
191	Management of Immune-Mediated Paraneoplastic Neurological Disorders. Neurology International Open, 2017, 01, E264-E274.	0.4	3
192	Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia. NPJ Schizophrenia, 2017, 3, 7.	2.0	84
193	Antiâ€contactinâ€associated proteinâ€2 encephalitis: relevance of antibody titres, presentation and outcome. European Journal of Neurology, 2017, 24, 175-186.	1.7	102

#	Article	IF	CITATIONS
194	Coexisting neuronal autoantibodies among children with demyelinating syndromes. Brain and Development, 2017, 39, 248-251.	0.6	1
195	Movement Disorders in an Adult Patient with antiâ€ <scp>NMDAR</scp> Encephalitis After Herpes Simplex Encephalitis. Movement Disorders Clinical Practice, 2017, 4, 460-462.	0.8	2
196	Extra–central nervous system target for assessment and treatment in refractory anti–N-methyl-d-aspartate receptor encephalitis. Journal of Critical Care, 2017, 37, 234-236.	1.0	13
197	<scp>NMDAR</scp> encephalitis: passive transfer from man to mouse by a recombinant antibody. Annals of Clinical and Translational Neurology, 2017, 4, 768-783.	1.7	101
198	Red Flags: Clinical Signs for Identifying Autoimmune Encephalitis in Psychiatric Patients. Frontiers in Psychiatry, 2017, 8, 25.	1.3	164
199	Clinical features of limbic encephalitis with LGI1 antibody. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 1589-1596.	1.0	55
201	Mechanisms of Autoantibody-Induced Pathology. Frontiers in Immunology, 2017, 8, 603.	2.2	377
202	Emerging clinical issues and multivariate analyses in PET investigations. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 386-404.	0.4	9
203	Anti-N-Methyl-D-aspartate Receptor Encephalitis: A Severe, Potentially Reversible Autoimmune Encephalitis. Mediators of Inflammation, 2017, 2017, 1-14.	1.4	66
204	N-Methyl-D-aspartate receptor antibody could be a cause of catatonic symptoms in psychiatric patients: case reports and methods for detection. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 339-345.	1.0	16
205	Paraneoplastic Anti-N-Methyl-D-Aspartic Acid Receptor Encephalitis. Chinese Medical Journal, 2017, 130, 2765-2766.	0.9	0
206	Case report of anti-N-methyl-D-aspartate receptor encephalitis in a middle-aged woman with a long history of major depressive disorder. BMC Psychiatry, 2017, 17, 320.	1.1	5
207	Hallmarks for early recognition of anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis: A case report and review of literature. Case Reports in Internal Medicine, 2017, 5, 9.	0.0	0
208	"Autoimmune Epilepsy― Encephalitis with Autoantibodies for Epileptologists. Epilepsy Currents, 2017, 17, 134-141.	0.4	64
210	Antibody-Mediated Encephalitis. New England Journal of Medicine, 2018, 378, 840-851.	13.9	812
211	Are naturally occurring anti-NMDAR autoantibodies pathogenic?. Nature Reviews Neurology, 2018, 14, 255-256.	4.9	1
212	A Systematic Review of the Neuropsychological Sequelae of People Diagnosed with Anti N-Methyl-D-Aspartate Receptor Encephalitis in the Acute and Chronic Phases. Archives of Clinical Neuropsychology, 2018, 33, 964-983.	0.3	16
213	Fulminant course in a patient with anti-N-methyl-D-aspartate receptor encephalitis with bilateral ovarian teratomas. Medicine (United States), 2018, 97, e0339.	0.4	11

#	Article	IF	CITATIONS
214	Clinical Characteristics and Prognosis of Severe Anti-N-methyl-d-aspartate Receptor Encephalitis Patients. Neurocritical Care, 2018, 29, 264-272.	1.2	45
215	Treating Immune-Related Epilepsy. Current Neurology and Neuroscience Reports, 2018, 18, 10.	2.0	12
216	Elevated neuron-specific enolase and S100 calcium-binding protein B concentrations in cerebrospinal fluid of patients with anti -N -methyl- d -aspartate receptor encephalitis. Clinica Chimica Acta, 2018, 480, 79-83.	0.5	19
217	N-methyl-D-aspartate receptor encephalitis: laboratory diagnostics and comparative clinical features in adults and children. Expert Review of Molecular Diagnostics, 2018, 18, 181-193.	1.5	14
218	Technological advances and changing indications for lumbar puncture in neurological disorders. Lancet Neurology, The, 2018, 17, 268-278.	4.9	65
219	Autoimmune Movement Disorders in Children. Seminars in Pediatric Neurology, 2018, 25, 92-112.	1.0	3
220	Bortezomib treatment for severe refractory antiâ€ <scp>NMDA</scp> receptor encephalitis. Annals of Clinical and Translational Neurology, 2018, 5, 598-605.	1.7	43
221	Elevated <scp>LGI</scp> 1″gG <scp>CSF</scp> index predicts worse neurological outcome. Annals of Clinical and Translational Neurology, 2018, 5, 646-650.	1.7	35
222	Absence of cerebrospinal fluid antineuronal antibodies in schizophrenia spectrum disorders. British Journal of Psychiatry, 2018, 212, 318-320.	1.7	37
223	Autoimmune encephalitis and psychiatric disorders. Revue Neurologique, 2018, 174, 228-236.	0.6	27
225	Autoimmune encephalitis (NMDAR antibody) in a patient receiving chronic post-transplant immunosuppression. Practical Neurology, 2018, 18, 320-322.	0.5	13
226	Extreme delta – With or without brushes: A potential surrogate marker of disease activity in anti-NMDA-receptor encephalitis. Clinical Neurophysiology, 2018, 129, 2197-2204.	0.7	28
227	Anti-N-methyl-d-aspartate receptor encephalitis in children: Incidence and experience in Hong Kong. Brain and Development, 2018, 40, 473-479.	0.6	29
228	Brain MRI Characteristics of Patients with Anti- <i>N</i> -Methyl-D-Aspartate Receptor Encephalitis and Their Associations with 2-Year Clinical Outcome. American Journal of Neuroradiology, 2018, 39, 824-829.	1.2	73
229	Anti-NMDA Receptor Encephalitis: Clinical Features and Basic Mechanisms. Advances in Pharmacology, 2018, 82, 235-260.	1.2	62
230	Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. Neurology, 2018, 90, e1386-e1394.	1.5	120
231	Anti-neuronal anti-bodies in patients with early psychosis. Schizophrenia Research, 2018, 192, 404-407.	1.1	38
232	Evaluation and Management of Autoimmune Encephalitis. Child and Adolescent Psychiatric Clinics of North America, 2018, 27, 37-52.	1.0	24

#	Article	IF	CITATIONS
233	Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain, 2018, 141, 13-36.	3.7	145
234	Serum complement levels in antiâ€ <i>N</i> â€methylâ€ <scp>d</scp> â€aspartate receptor encephalitis. European Journal of Neurology, 2018, 25, 178-184.	1.7	13
235	Autoimmune Encephalitis in Children. Journal of Pediatric Neurology, 2018, 16, 192-201.	0.0	1
236	Treatment strategies for autoimmune encephalitis. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628561772234.	1.5	156
238	Brain-relevant antibodies in first-episode psychosis: a matched case–control study. Psychological Medicine, 2018, 48, 1257-1263.	2.7	22
239	Paraneoplastic Syndromes of the Nervous System as Complications of Cancer. , 2018, , 221-238.		1
240	Neurologic Complications of Female Reproductive Tract Cancers. , 2018, , 497-513.		1
241	Superficial white matter damage in anti-NMDA receptor encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 518-525.	0.9	55
242	Psychiatric syndromes other than dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 285-296.	1.0	8
243	Encefalitis por anticuerpos contra el receptor de NMDA. Medicina ClÃnica, 2018, 151, 71-79.	0.3	39
244	No neuronal autoantibodies detected in plasma of patients with a bipolar I disorder. Psychiatry Research, 2018, 259, 460-462.	1.7	2
245	Successful treatment of anti-NMDA receptor encephalitis with early teratoma removal and plasmapheresis. Medicine (United States), 2018, 97, e11325.	0.4	10
246	A Case of Severe Anti-N-Methyl D-Aspartate (Anti-NMDA) Receptor Encephalitis with Refractory Autonomic Instability and Elevated Intracranial Pressure. American Journal of Case Reports, 2018, 19, 1216-1221.	0.3	12
247	Utility and Safety of Intrathecal Methotrexate Treatment in Severe Anti-N-methyl-D-aspartate Receptor Encephalitis. Chinese Medical Journal, 2018, 131, 156-160.	0.9	25
248	Updates in the Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes. Current Oncology Reports, 2018, 20, 92.	1.8	64
250	Elevated Soluble Fas and FasL in Cerebrospinal Fluid and Serum of Patients With Anti-N-methyl-D-aspartate Receptor Encephalitis. Frontiers in Neurology, 2018, 9, 904.	1.1	20
251	Alpha7 acetylcholine receptor autoantibodies are rare in sera of patients diagnosed with schizophrenia or bipolar disorder. PLoS ONE, 2018, 13, e0208412.	1.1	9
252	Management of Autoimmune Encephalitis: An Observational Monocentric Study of 38 Patients. Frontiers in Immunology, 2018, 9, 2708.	2.2	21

#	Article	IF	CITATIONS
253	Prognosis in autoimmune encephalitis: Database. Data in Brief, 2018, 21, 2694-2703.	0.5	4
254	Anti-NMDA receptor encephalitis presenting as isolated aphasia in an adult. Neurocase, 2018, 24, 188-194.	0.2	7
255	Detection Methods for Autoantibodies in Suspected Autoimmune Encephalitis. Frontiers in Neurology, 2018, 9, 841.	1.1	60
256	The clinical features, underlying immunology, and treatment of autoantibodyâ€mediated movement disorders. Movement Disorders, 2018, 33, 1376-1389.	2.2	44
257	Antibody-Associated Autoimmune Encephalitis and Epilepsies in Children. Journal of Pediatric Epilepsy, 2018, 07, 040-044.	0.1	1
258	Anti-NMDAR Encephalitis in a 13-Year-Old Female: A 24-Month Clinical Follow-Up. Journal of Epilepsy Research, 2018, 8, 41-48.	0.1	1
259	Affinities of human NMDA receptor autoantibodies: implications for disease mechanisms and clinical diagnostics. Journal of Neurology, 2018, 265, 2625-2632.	1.8	32
260	Autoimmune Epilepsy: New Development and Future Directions. , 2018, , .		1
261	Pathogenicity of Antibodies against NMDA Receptor: Molecular Insights into Autoimmune Psychosis. Trends in Neurosciences, 2018, 41, 502-511.	4.2	23
262	Pearls & Oy-sters: Relapse of anti-NMDA receptor encephalitis after prior first- and second-line immunotherapy. Neurology, 2018, 90, 936-939.	1.5	9
263	Postherpes simplex encephalitis: a case series of viral-triggered autoimmunity, synaptic autoantibodies and response to therapy. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641876877.	1.5	33
264	Pediatric Inflammatory Brain Disease. , 2018, , 169-188.		0
265	Autoimmune encephalitis: a review of diagnosis and treatment. Arquivos De Neuro-Psiquiatria, 2018, 76, 41-49.	0.3	84
266	Membrane-bound and soluble forms of an NMDA receptor extracellular domain retain epitopes targeted in auto-immune encephalitis. BMC Biotechnology, 2018, 18, 41.	1.7	4
267	A Patient With Encephalomyeloradiculoneuropathy Exhibiting a Relapsing–Remitting Clinical Course: Correlation of Serum and Cerebrospinal Fluid Anti-Neutral Glycosphingolipids Antibodies With Clinical Relapse. Frontiers in Neurology, 2018, 9, 206.	1.1	8
268	Diagnostic and Therapeutic Approach to Autoimmune Neurologic Disorders. Seminars in Neurology, 2018, 38, 392-402.	0.5	22
269	An Overview of Autoimmune and Paraneoplastic Encephalitides. Seminars in Neurology, 2018, 38, 330-343.	0.5	25
270	Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies. Journal of Neurology, 2018, 265, 2190-2200.	1.8	64

#	Article	IF	Citations
271	Meningitis and Encephalitis., 2018,,.		5
272	Autoimmune Encephalitis., 2018, , 175-190.		0
273	A clinical approach to new-onset psychosis associated with immune dysregulation: the concept of autoimmune psychosis. Journal of Neuroinflammation, 2018, 15, 40.	3.1	62
274	Anti-NMDA receptor encephalitis in a toddler. International Journal of Pediatrics and Adolescent Medicine, 2018, 5, 75-77.	0.5	8
275	Autoimmune Encephalitis. , 2018, , 193-216.		2
276	Mesial temporal lobe epilepsy with hippocampal sclerosis is infrequently associated with neuronal autoantibodies. Epilepsia, 2018, 59, e152-e156.	2.6	27
277	Predictive value of electroencephalography in anti-NMDA receptor encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1101-1106.	0.9	58
278	Therapeutic plasma exchange in paediatric neurology: a critical review and proposed treatment algorithm. Developmental Medicine and Child Neurology, 2018, 60, 765-779.	1.1	24
279	Encephalitis associated with antibodies against the NMDA receptor. Medicina ClÃnica (English Edition), 2018, 151, 71-79.	0.1	11
280	Paraneoplastic Neurologic Syndromes. Neurologic Clinics, 2018, 36, 675-685.	0.8	41
281	Neuroimmune disorders of the central nervous system in children in the molecular era. Nature Reviews Neurology, 2018, 14, 433-445.	4.9	41
282	Pediatric Relapsing Anti-NMDAR Encephalitis Crossing with Tumefactive Demyelinating Lesion. Journal of Pediatric Neurology, 2019, 17, 077-084.	0.0	1
283	Human Stem Cellâ€"Derived Models: Lessons for Autoimmune Diseases of the Nervous System. Neuroscientist, 2019, 25, 199-207.	2.6	3
284	<i>N</i> -Methyl- <scp>d</scp> -aspartate Receptor Antibody Encephalitis: A Concise Review of the Disorder, Diagnosis, and Management. ACS Chemical Neuroscience, 2019, 10, 132-142.	1.7	22
285	Limbic Encephalitis in Patients with Epilepsyâ€"is Quantitative MRI Diagnostic?. Clinical Neuroradiology, 2019, 29, 623-630.	1.0	4
286	Severe relapse of anti-NMDA receptor encephalitis 5†years after initial symptom onset. ENeurologicalSci, 2019, 16, 100199.	0.5	3
287	Significance of Autoantibodies. , 2019, , 109-142.		0
288	The Evolution of Movement Disorders in Nâ€Methylâ€Dâ€Aspartate Receptor Encephalitis—A Video Log. Movement Disorders Clinical Practice, 2019, 6, 610-611.	0.8	0

#	Article	IF	CITATIONS
289	The clinical significance of atypical indirect immunofluorescence patterns on primate cerebellum in paraneoplastic antibody screening. Autoimmunity Highlights, 2019, 10, 6.	3.9	2
290	An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurology, The, 2019, 18, 1045-1057.	4.9	497
291	Elevated CHI3L1 and OPN levels in patients with anti-N-methyl-d-aspartate receptor encephalitis. Journal of Neuroimmunology, 2019, 334, 577005.	1.1	12
292	Autoimmunity in psychotic disorders. Where we stand, challenges and opportunities. Autoimmunity Reviews, 2019, 18, 102348.	2.5	30
293	New Onset British Accent, Acute Behavioral Changes, and Seizures: A Unique Presentation of NMDAR Encephalitis. Case Reports in Neurological Medicine, 2019, 2019, 1-5.	0.3	0
294	Autoantibodies and Psychosis. Current Topics in Behavioral Neurosciences, 2019, 44, 85-123.	0.8	6
295	Surface Antibody-Mediated Autoimmune Encephalitis. , 2019, , 159-168.		0
296	Cerebrospinal Fluid Findings in Patients With Autoimmune Encephalitis—A Systematic Analysis. Frontiers in Neurology, 2019, 10, 804.	1.1	123
297	Anti-NMDA-receptor antibody in initial diagnosis of mood disorder. European Neuropsychopharmacology, 2019, 29, 1041-1050.	0.3	8
299	Management of Autoimmune Encephalitis in the Neurocritical Care Unit., 2019,, 233-237.		0
300	Neurorheumatology., 2019,,.		2
301	The immunobiology of autoimmune encephalitides. Journal of Autoimmunity, 2019, 104, 102339.	3.0	44
302	Atypical presentation of MOG-related disease: Slowly progressive behavioral and personality changes following a seizure. Multiple Sclerosis and Related Disorders, 2019, 36, 101394.	0.9	7
303	Cerebellar ataxia as a presenting symptom in a patient with anti-NMDA receptor encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e579.	3.1	13
304	B cells in autoimmune and neurodegenerative central nervous system diseases. Nature Reviews Neuroscience, 2019, 20, 728-745.	4.9	190
305	Epidemiology of Antibody-Positive Autoimmune Encephalitis in Southwest China: A Multicenter Study. Frontiers in Immunology, 2019, 10, 2611.	2.2	50
306	Early multidisciplinary intensive-care therapy can improve outcome of severe anti-NMDA-receptor encephalitis presenting with extreme delta brush. Translational Neuroscience, 2019, 10, 241-243.	0.7	4
307	The diffuse involvement of anti-N-methyl-D-aspartate receptor encephalitis in brain: a case report. BMC Neurology, 2019, 19, 230.	0.8	2

#	Article	IF	Citations
308	Brain astrocytoma misdiagnosed as anti-NMDAR encephalitis: a case report. BMC Neurology, 2019, 19, 210.	0.8	12
310	Pediatric Autoimmune Encephalitis: Case Series From Two Chinese Tertiary Pediatric Neurology Centers. Frontiers in Neurology, 2019, 10, 906.	1.1	37
311	Relevance of Surface Neuronal Protein Autoantibodies as Biomarkers in Seizure-Associated Disorders. International Journal of Molecular Sciences, 2019, 20, 4529.	1.8	5
312	Surgical outcomes in patients with anti-N-methyl D-aspartate receptor encephalitis with ovarian teratoma. American Journal of Obstetrics and Gynecology, 2019, 221, 485.e1-485.e10.	0.7	35
313	Innate Immunity in the Central Nervous System: A Missing Piece of the Autoimmune Encephalitis Puzzle?. Frontiers in Immunology, 2019, 10, 2066.	2.2	53
315	Autoimmune encephalitis. Neurology, 2019, 92, e964-e972.	1.5	41
316	Epilepsy in adults. Lancet, The, 2019, 393, 689-701.	6.3	1,067
317	Diagnosing autoimmune encephalitis based on clinical features and autoantibody findings. Expert Review of Clinical Immunology, 2019, 15, 511-527.	1.3	10
318	Diagnostic tools for immune causes of encephalitis. Clinical Microbiology and Infection, 2019, 25, 431-436.	2.8	13
319	Recognizing psychiatric presentations of antiâ€NMDA receptor encephalitis in children and adolescents: A synthesis of published reports. Psychiatry and Clinical Neurosciences, 2019, 73, 262-268.	1.0	27
320	Autoimmune encephalitis associated with antibodies against the metabotropic glutamate receptor type 1: case report and review of the literature. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984741.	1.5	12
321	Paraneoplastic movement disorders: phenomenology, diagnosis, and treatment. European Journal of Internal Medicine, 2019, 67, 14-23.	1.0	11
322	Novel Object Recognition in Rats With NMDAR Dysfunction in CA1 After Stereotactic Injection of Anti-NMDAR Encephalitis Cerebrospinal Fluid. Frontiers in Neurology, 2019, 10, 586.	1.1	26
323	Autoimmune Epilepsy. Neurotherapeutics, 2019, 16, 685-702.	2.1	83
324	Management of antibody-mediated autoimmune encephalitis in adults and children: literature review and consensus-based practical recommendations. Neurological Sciences, 2019, 40, 2017-2030.	0.9	57
325	N-Methyl-D-Aspartate Receptor Encephalitis with Psychiatric Symptoms and an Ovarian Teratoma Detected by MRI in a 17-Year-Old Girl. Neuropediatrics, 2019, 50, 253-256.	0.3	1
326	Clinical Characteristics and Short-Term Prognosis of Autoimmune Encephalitis: A Single-Center Cohort Study in Changsha, China. Frontiers in Neurology, 2019, 10, 539.	1.1	35
328	Clinical Features and Inflammatory Markers in Autoimmune Encephalitis Associated With Antibodies Against Neuronal Surface in Brazilian Patients. Frontiers in Neurology, 2019, 10, 472.	1.1	16

#	ARTICLE	IF	CITATIONS
329	The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies. Brain, 2019, 142, 1631-1643.	3.7	73
330	First known case of catatonia due to cyclosporine A-related neurotoxicity in a pediatric patient with steroid-resistant nephrotic syndrome. BMC Psychiatry, 2019, 19, 123.	1.1	12
331	Epilepsy Associated with Inflammatory and Immunological Diseases of the Central Nervous System. , 2019, , 735-748.		1
332	Anti-N-methyl-d-aspartate receptor encephalitis in an older patient presenting with a rapid onset of delusions and amnesia. BMJ Case Reports, 2019, 12, e228512.	0.2	2
333	Severe tooth loss secondary to orofacial dyskinesias in anti-NMDA receptor encephalitis. BMJ Case Reports, 2019, 12, e228380.	0.2	3
334	Automatisation. Springer Reference Medizin, 2019, , 389-389.	0.0	0
335	Encephalitis, Mild Encephalitis, Neuroprogression, or Encephalopathyâ€"Not Merely a Question of Terminology. Frontiers in Psychiatry, 2018, 9, 782.	1.3	13
336	Anti-N-Methyl-D-Aspartate Encephalitis as Paraneoplastic Manifestation of Germ-Cells Tumours: A Cases Report and Literature Review. Case Reports in Immunology, 2019, 2019, 1-6.	0.2	1
337	Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABA <sub>B</sub> R encephalitis. Neurology, 2019, 92, e2185-e2196.	1.5	188
338	Autoimmune Encephalitides and Rapidly Progressive Dementias. Seminars in Neurology, 2019, 39, 283-292.	0.5	9
339	Pediatric autoimmune encephalitis in Denmark during 2011–17: A nationwide multicenter population-based cohort study. European Journal of Paediatric Neurology, 2019, 23, 639-652.	0.7	25
340	A mouse model of seizures in anti– <i>N</i> àêmethylâ€ <scp>d</scp> â€aspartate receptor encephalitis. Epilepsia, 2019, 60, 452-463.	2.6	46
341	Acute encephalitis in immunocompetent adults. Lancet, The, 2019, 393, 702-716.	6.3	86
342	Limbic encephalitis with positivity for anti-flotillin antibodies in serum and CSF. Neurology: Clinical Practice, 2019, 11, 10.1212/CPJ.00000000000741.	0.8	4
343	Horizontal saccadic palsy as a prominent symptom of anti-NMDAR encephalitis. Neurology: Clinical Practice, 2019, 11, 10.1212/CPJ.000000000000550.	0.8	0
344	Anti-NMDAR Encephalitis: Higher Suspicious Needed for Earlier Diagnosis (Case Report, Literature) Tj ETQq1 1 C	.784314 rg	gBT <sub>4</sub> /Overlock
345	Understanding Childhood Neuroimmune Diseases of the Central Nervous System. Frontiers in Pediatrics, 2019, 7, 511.	0.9	23
346	Immune-mediated encephalitis for the infectious disease specialist. Current Opinion in Infectious Diseases, 2019, 32, 251-258.	1.3	12

#	Article	IF	CITATIONS
347	Hemiencephalitis: a hyperaemic presentation of Hashimoto's encephalopathy. BMJ Case Reports, 2019, 12, e230011.	0.2	1
348	Anti-NMDA-receptor Encephalitis in an Adolescent With HIV Infection and Review of the Literature. Pediatric Infectious Disease Journal, 2019, 38, e169-e171.	1.1	4
349	Psychosis of dual origin in HIV infection. Neurology: Clinical Practice, 2019, 9, 178-180.	0.8	2
350	A young man in "double-trouble― Hallucinations and cranial nerve palsies. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e526.	3.1	1
351	NMDAR encephalitis presenting as akinesia in a patient with Parkinson disease. Journal of Neuroimmunology, 2019, 328, 35-37.	1.1	5
352	Clinical variability of children with anti-N-methyl-d-aspartate receptor encephalitis in southern Brazil: a cases series and review of the literature. Neurological Sciences, 2019, 40, 351-356.	0.9	11
353	Clinical manifestations, treatment outcomes, and prognostic factors of pediatric anti-NMDAR encephalitis in tertiary care hospitals: A multicenter retrospective/prospective cohort study. Brain and Development, 2019, 41, 436-442.	0.6	21
354	Movement disorders associated with neuronal antibodies. Acta Neurologica Scandinavica, 2019, 139, 106-117.	1.0	9
355	Pediatric Neuropsychiatry., 2019, , .		1
356	Prognosticating autoimmune encephalitis: A systematic review. Journal of Autoimmunity, 2019, 96, 24-34.	3.0	115
357	Prediction of neutrophil-to-lymphocyte ratio in the diagnosis and progression of autoimmune encephalitis. Neuroscience Letters, 2019, 694, 129-135.	1.0	36
358	The princess and the <i>p</i> -value: A case report of suspected autoimmune encephalitis and functional neurological disorder in a pediatric patient. Applied Neuropsychology: Child, 2020, 9, 13-20.	0.7	2
359	Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis. Multiple Sclerosis Journal, 2020, 26, 333-342.	1.4	37
360	"Relapsing encephalopathy with dancing eyes and jerky limbs― Expert commentary. Parkinsonism and Related Disorders, 2020, 75, 114-115.	1.1	O
361	Serum and CSF Anti-NMDAR Antibody Testing in Psychiatry. Journal of Neuropsychiatry and Clinical Neurosciences, 2020, 32, 154-160.	0.9	16
362	Psychiatric Presentation of Probable Seronegative Autoimmune Encephalitis in a Late Middle-Aged Woman With Ovarian Teratoma. Psychosomatics, 2020, 61, 288-295.	2.5	3
363	Testing for <i>N</i> -methyl- <scp>d</scp> -aspartate Receptor Autoantibodies in Clinical Practice. Canadian Journal of Neurological Sciences, 2020, 47, 69-76.	0.3	6
364	Autoimmune and Autoantibody-Associated Encephalomyelopathies. , 2020, , 1067-1114.		1

#	Article	IF	CITATIONS
365	Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry, the, 2020, 7, 93-108.	3.7	252
366	Anti-N-methyl-D-aspartate receptor encephalitis with accompanying ovarian teratoma in female patients from East China: Clinical features, treatment, and prognostic outcomes. Seizure: the Journal of the British Epilepsy Association, 2020, 75, 55-62.	0.9	14
367	Anti-N-methyl-D-aspartate receptor encephalitis: A review of pathogenic mechanisms, treatment, prognosis. Brain Research, 2020, 1727, 146549.	1.1	47
368	Anti-NMDAR encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	106
369	Delayed N-methyl-D-aspartate Receptor Encephalitis Relapse. Canadian Journal of Neurological Sciences, 2020, 47, 264-266.	0.3	1
370	Overlapping autoimmune syndrome: A case of concomitant anti-NMDAR encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease. Journal of Neuroimmunology, 2020, 339, 577124.	1.1	21
371	Neuroimmunological antibody-mediated encephalitis and implications for diagnosis and therapy in neuropsychiatry. Acta Neuropsychiatrica, 2020, 32, 177-185.	1.0	5
372	Primary HIV infection presenting with Kaposi sarcoma and limbic encephalitis. Journal of NeuroVirology, 2020, 26, 292-296.	1.0	4
373	Headache, Delirium or Encephalitis? A Case of Residual Mutism Secondary to Anti-NMDA Receptor Encephalitis. Case Reports in Neurology, 2020, 11, 330-343.	0.3	3
374	Anti- <i>N</i> -methyl-D-aspartate receptor encephalitis in a young female with subclinical hypothyroidism associated with anti-thyroid peroxidase and anti-thyroglobulin antibodies: A case report. SAGE Open Medical Case Reports, 2020, 8, 2050313X2094978.	0.2	1
375	Pediatric Inflammatory and Autoimmune Neurologic Disorders at a Tertiary Medical Center. Journal of Child Neurology, 2020, 35, 949-952.	0.7	1
376	Solitary juxtacortical lesion associated with anti-N-methyl-D-aspartate receptor encephalitis: a case report. BMC Neurology, 2020, 20, 421.	0.8	0
377	Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis. Clinical Chemistry, 2020, 66, 1496-1509.	1.5	41
378	Cerebrospinal Fluid Osteopontin and Inflammation-Associated Cytokines in Patients With Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Frontiers in Neurology, 2020, 11, 519692.	1.1	6
379	Autoantibodies to the N-Methyl-D-Aspartate Receptor in Adolescents With Early Onset Psychosis and Healthy Controls. Frontiers in Psychiatry, 2020, 11, 666.	1.3	7
380	The B cell immunobiology that underlies CNS autoantibody-mediated diseases. Nature Reviews Neurology, 2020, 16, 481-492.	4.9	47
381	Study of B Cell Repertoire in Patients With Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Frontiers in Immunology, 2020, 11, 1539.	2.2	9
382	Association of thyroid peroxidase antibodies with anti-neuronal surface antibodies in health, depression and schizophrenia – Complementary linkage with somatic symptoms of major depression. Brain, Behavior, and Immunity, 2020, 90, 47-54.	2.0	13

#	Article	IF	Citations
383	Autoimmune Encephalitis in Children: An Update. Indian Pediatrics, 2020, 57, 662-670.	0.2	18
384	Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis. Translational Psychiatry, 2020, 10, 279.	2.4	57
385	Commentary: Epidemiology of Antibody-Positive Autoimmune Encephalitis in Southwest China: A Multicenter Study. Frontiers in Immunology, 2020, 11, 1976.	2.2	0
387	Apheresis in Autoimmune Encephalitis and Autoimmune Dementia. Journal of Clinical Medicine, 2020, 9, 2683.	1.0	13
388	Neuro-Ophthalmic Features of Autoimmune Encephalitides. Journal of Neuro-Ophthalmology, 2020, 40, 385-397.	0.4	9
389	Clinical and EEG characteristics analysis of autoimmune encephalitis in children with positive and negative anti-N-methyl- D-aspartate receptor antibodies. Annals of Palliative Medicine, 2020, 9, 2575-2585.	0.5	4
392	Autoimmune encephalitis mediated by B-cell response against N-methyl-d-aspartate receptor. Brain, 2020, 143, 2957-2972.	3.7	39
393	Fecal microbiota transplantation from patients with autoimmune encephalitis modulates Th17 response and relevant behaviors in mice. Cell Death Discovery, 2020, 6, 75.	2.0	13
394	Cytokines/Chemokines: Potential Biomarkers for Non-paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Frontiers in Neurology, 2020, 11, 582296.	1.1	18
395	Lipid profiles and their potential inflammatoryÂeffects in anti-N-methyl-D-aspartate receptor encephalitis. Neurological Sciences, 2020, 42, 2881-2890.	0.9	3
396	Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis. Frontiers in Neurology, 2020, 11, 602102.	1.1	28
397	Atypical presentation of anti-N-methyl-D-aspartate receptor encephalitis in a 61-year-old Hispanic man. BMJ Case Reports, 2020, 13, e238347.	0.2	3
398	E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology, 2020, 29, 22-31.	0.7	24
399	CSF studies which ultimately led to the possible diagnosis of anti-NMDAR encephalitis. BMJ Case Reports, 2020, 13, e233489.	0.2	1
400	Mind the Gap: Seronegative but Cerebrospinal Fluid Antibodyâ€Positive Anti―N â€Methylâ€Dâ€Aspartate Receptor Encephalitis. Movement Disorders Clinical Practice, 2020, 7, 500-501.	0.8	0
401	Evaluation of the proposed antiâ€Nâ€methylâ€∢scp>dâ€espartate receptor encephalitis clinical diagnostic criteria in psychiatric patients. Acta Psychiatrica Scandinavica, 2020, 142, 52-57.	2.2	4
402	Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	29
403	Are aquaporin antibody titers useful outcome measures for neuromyelitis optica spectrum disorders?. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	3

#	Article	IF	Citations
404	Anti-NMDA receptor encephalitis associated with ovarian tumor: the gynecologist point of view. Archives of Gynecology and Obstetrics, 2020, 302, 315-320.	0.8	12
405	Prevalence of N-Methyl-d-Aspartate Receptor antibody (NMDAR-Ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study. Schizophrenia Research, 2020, 222, 455-461.	1.1	17
406	Limbic encephalitis with antibodies to N-methyl-d-aspartate (NMDA)-type glutamate receptor after allogeneic transplantation. International Journal of Hematology, 2020, 112, 254-257.	0.7	7
407	Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis: clinical symptomatology, pathophysiology, diagnostic approach, and therapeutic considerations. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 803-818.	1.8	59
408	Immune processes and risk of psychosis. , 2020, , 211-227.		0
409	Mercury-induced autoimmunity: Report of two adolescent siblings with Morvan syndrome "plus―and review of the literature. Journal of Neuroimmunology, 2020, 342, 577197.	1.1	6
410	Confounders in the Interpretation of Paraneoplastic and Neuronal Autoantibody Panels. Clinics in Laboratory Medicine, 2020, 40, 305-316.	0.7	3
411	Receptor autoimmunity: diagnostic and therapeutic implications. Autoimmunity Highlights, 2020, 11, 1.	3.9	12
412	Pediatric autoimmune encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	40
413	Understanding the tests that we order: screening for anti-NMDA receptor encephalitis in first episode psychosis. Australasian Psychiatry, 2020, 28, 199-201.	0.4	3
414	Treatable Movement Disorders of Infancy and Early Childhood. Seminars in Neurology, 2020, 40, 177-191.	0.5	3
415	Autoimmune encephalitis in children and adolescents. Neurological Research and Practice, 2020, 2, 4.	1.0	13
416	Pregnancy outcomes in anti-NMDA receptor encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	30
417	Autoimmune encephalitis management: MS centers and beyond. Multiple Sclerosis Journal, 2020, 26, 1618-1626.	1.4	5
418	Neurological complications of pediatric cancer. Cancer and Metastasis Reviews, 2020, 39, 3-23.	2.7	20
419	Paraneoplastic Neurologic Syndromes. , 2020, , 676-687.e5.		1
421	Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program. Frontiers in Neurology, 2019, 10, 1385.	1.1	26
422	Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome. Journal of Neurology, 2020, 267, 2101-2114.	1.8	40

#	Article	IF	CITATIONS
424	Clinical analysis of anti-NMDAR encephalitis combined with MOG antibody in children. Multiple Sclerosis and Related Disorders, 2020, 42, 102018.	0.9	34
425	Current Progress on Assessing the Prognosis for Anti-N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis. BioMed Research International, 2020, 2020, 1-8.	0.9	13
426	Neurocritical care for Anti-NMDA receptor encephalitis. Biomedical Journal, 2020, 43, 251-258.	1.4	15
427	N2 year in review. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e644.	3.1	1
428	Early Bortezomib Therapy for Refractory Anti-NMDA Receptor Encephalitis. Frontiers in Neurology, 2020, 11, 188.	1.1	20
429	Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e659.	3.1	30
430	Clinical characteristics and long-term prognosis of relapsing anti-N-methyl-d-aspartate receptor encephalitis: a retrospective, multicenter, self-controlled study. Neurological Sciences, 2021, 42, 199-207.	0.9	7
431	Longitudinal measurement of cerebrospinal fluid neurofilament light in antiâ€Nâ€methylâ€Dâ€aspartate receptor encephalitis. European Journal of Neurology, 2021, 28, 1401-1405.	1.7	12
432	Autoimmunity and NMDA receptor in brain disorders: Where do we stand?. Neurobiology of Disease, 2021, 147, 105161.	2.1	13
433	Seizures associated with antibodies against cell surface antigens are acute symptomatic and not indicative of epilepsy: insights from long-term data. Journal of Neurology, 2021, 268, 1059-1069.	1.8	20
434	Long-term persistence of NMDAR antibodies after encephalitis with de novo occurrence of demyelinating disorder. Neurological Sciences, 2021, 42, 301-303.	0.9	4
435	Critical Analysis of a Challenging Case of Post-Infectious N-Methyl-D-Aspartate Receptor Encephalitis. Neurohospitalist, The, 2021, 11, 160-164.	0.3	0
436	Muddying the waters? A false positive case of autoimmune psychosis. Australasian Psychiatry, 2021, 29, 278-281.	0.4	1
437	Preparation of glycan-oriented imprinted polymer coating Gd-doped silicon nanoparticles for targeting cancer Tn antigens and dual-modal cell imaging via boronate-affinity surface imprinting. Talanta, 2021, 223, 121706.	2.9	15
438	Practical approach for the diagnosis of disorders associated with antibodies against neuronal surface proteins. Neurology and Clinical Neuroscience, 2021, 9, 56-62.	0.2	3
439	Inflammation, ictogenesis, and epileptogenesis: An exploration through human disease. Epilepsia, 2021, 62, 303-324.	2.6	40
440	NMDAR antibodies in patients with psychosis. Lancet Psychiatry, the, 2021, 8, 88-89.	3.7	1
442	Distinct cerebral 18F-FDG PET metabolic patterns in anti-N-methyl-D-aspartate receptor encephalitis patients with different trigger factors. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199563.	1.5	8

#	Article	IF	CITATIONS
443	Autoantibodies detection in anti-N-methyl-D-aspartate receptor encephalitis. Annals of Translational Medicine, $2021$ , .	0.7	0
444	Comparison of N-methyl-d-aspartate receptor antibody assays using live or fixed substrates. Journal of Neurology, 2021, 268, 1818-1826.	1.8	9
445	Autoantibodies, Encephalopathies, and Epilepsy. Agents and Actions Supplements, 2021, , 125-147.	0.2	0
446	Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. Brain Communications, 2021, 3, fcaa233.	1.5	31
447	Spectrum of anti-NMDA receptor antibody encephalitis: Clinical profile, management and outcomes. Annals of Indian Academy of Neurology, 2021, 24, 383.	0.2	7
448	The Peculiar Clinical Symptoms and Treatment of Limbic Encephalitis Associated with AMPA Receptor Antibody. European Neurology, 2021, 84, 206-211.	0.6	5
449	Neurologic disorders. , 2021, , 1023-1056.		0
450	Sleep Disturbances Associated with Neurological Autoimmunity. Neurotherapeutics, 2021, 18, 181-201.	2.1	11
451	Influential factors and predictors of anti-N-methyl-D-aspartate receptor encephalitis associated with severity at admission. Neurological Sciences, 2021, 42, 3835-3841.	0.9	7
452	Treatment Approaches in Autoimmune Neurology: Focus on Autoimmune Encephalitis with Neuronal Cell Surface Antibodies., 2021,, 261-278.		1
453	Long-term Functional Outcomes and Relapse of Anti-NMDA Receptor Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	44
454	Neural Antibody Testing for Autoimmune Encephalitis: A Canadian Single-Centre Experience. Canadian Journal of Neurological Sciences, 2021, , 1-5.	0.3	9
455	Strange Behavior in a Transgender Teenager. Pediatrics in Review, 2021, 42, 100-102.	0.2	1
456	Limbic encephalitis in a patient with systemic lupus erythematosus successfully treated with high-dose glucocorticoids and intravenous cyclophosphamide therapy: the potential pathogenicity of anti-glutamate receptor antibodies. Modern Rheumatology Case Reports, 2021, 5, 250-253.	0.3	1
457	The search for an autoimmune origin of psychotic disorders: Prevalence of autoantibodies against hippocampus antigens, glutamic acid decarboxylase and nuclear antigens. Schizophrenia Research, 2021, 228, 462-471.	1.1	6
458	Anti-NMDAR encephalitis induced in mice by active immunization with a peptide from the amino-terminal domain of the GluN1 subunit. Journal of Neuroinflammation, 2021, 18, 53.	3.1	17
459	Rituximab Was Effective for Treatment of Anti–N-Methyl-d-Aspartate Receptor Encephalitis in Early Adolescence in Initially Suspected Dissociative Disorder. Clinical Neuropharmacology, 2021, 44, 99-100.	0.2	1
460	Anti-NMDAR Encephalitis with Relapsing Optic Neuritis. Neuroscience and Behavioral Physiology, 2021, 51, 163-170.	0.2	0

#	Article	IF	Citations
462	Characteristics and outcomeâ€related factors of seizure at the first onset of autoimmune encephalitis: A retrospective study. CNS Neuroscience and Therapeutics, 2021, 27, 694-701.	1.9	7
463	Tofacitinib treatment for refractory autoimmune encephalitis. Epilepsia, 2021, 62, e53-e59.	2.6	16
464	Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	43
465	Longitudinal CSF Findings in Autoimmune Encephalitis—A Monocentric Cohort Study. Frontiers in Immunology, 2021, 12, 646940.	2.2	18
466	Neural Autoantibodies in Cerebrospinal Fluid and Serum in Clinical High Risk for Psychosis, First-Episode Psychosis, and Healthy Volunteers. Frontiers in Psychiatry, 2021, 12, 654602.	1.3	19
467	Prevalence of Neural Autoantibodies in Epilepsy of Unknown Etiology: Systematic Review and Meta-Analysis. Brain Sciences, 2021, 11, 392.	1.1	5
468	Super-resolving Microscopy in Neuroscience. Chemical Reviews, 2021, 121, 11971-12015.	23.0	40
469	Case Report: Antibodies to the N-Methyl-D-Aspartate Receptor in a Patient With Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 664364.	2.2	4
470	Autoimmune Disorders of the Nervous System: Pathophysiology, Clinical Features, and Therapy. Frontiers in Neurology, 2021, 12, 664664.	1.1	37
471	Symptomatologic pathomechanism of N-methyl D-aspartate receptor encephalitis. Encephalitis, 2021, 1, 36-44.	0.3	0
473	Antibody-Mediated Encephalitis in Children: Focus on Diagnostic Clues and Acute Symptom Management. Seminars in Pediatric Neurology, 2021, 37, 100873.	1.0	3
474	Autoimmune Encephalitis in First Episode Psychoses. Neurology, 2021, 97, 16-17.	1.5	5
475	Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. Neurology, 2021, 97, e61-e75.	1.5	54
476	Autoimmune encephalitis in a South Asian population. BMC Neurology, 2021, 21, 203.	0.8	7
477	Clinical Review and Prognostic Analysis of α-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionate Receptor-Associated Encephalitis. Frontiers in Neurology, 2021, 12, 665229.	1.1	2
478	Validation of Predictive Models for Autoimmune Encephalitis-Related Antibodies to Cell-Surface Proteins Expressed in Neurons: A Retrospective Study Based in a Hospital. Frontiers in Neurology, 2021, 12, 601761.	1.1	5
479	Autoimmune Encephalitis in Tunisia: Report of a Pediatric Cohort. Journal of Immunology Research, 2021, 2021, 1-7.	0.9	7
480	Antibodies against N-Methyl D-Aspartate Receptor in Psychotic Disorders: A Systematic Review. Neuropsychobiology, 2022, 81, 1-18.	0.9	5

#	ARTICLE	IF	CITATIONS
481	"Antibody of Unknown Significance―(AUS): The Issue of Interpreting Antibody Test Results. Movement Disorders, 2021, 36, 1543-1547.	2.2	11
482	Case Report: Severe Adolescent Major Depressive Syndrome Turns Out to Be an Unusual Case of Anti-NMDA Receptor Encephalitis. Frontiers in Psychiatry, 2021, 12, 679996.	1.3	5
483	Anti-N-Methyl-D-Aspartate Receptor Encephalitis Associated with Ovarian Teratoma in South China-Clinical Features, Treatment, Immunopathology, and Surgical Outcomes of 21 Cases. Disease Markers, 2021, 2021, 1-7.	0.6	6
484	Pathogenesis, diagnosis and treatment of paraneoplastic neurologic syndromes. Expert Review of Neurotherapeutics, 2021, 21, 675-686.	1.4	6
485	Autoantibodies in neurological disease. Nature Reviews Immunology, 2021, 21, 798-813.	10.6	147
486	Anti-NMDAR encephalitis for psychiatrists: the essentials. BJPsych Bulletin, 2022, 46, 235-241.	0.7	5
487	Refractory NMDA-receptor encephalitis in a teenager: A novel use of Bortezomib. Journal of Neuroimmunology, 2021, 355, 577565.	1.1	3
488	Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis. Frontiers in Immunology, 2021, 12, 691536.	2.2	46
489	International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	70
490	A role for pathogen risk factors and autoimmunity in encephalitis lethargica?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 109, 110276.	2.5	2
491	Temporal rank of clinical characteristics and prognosis of antiâ€ <i>N</i> â€methylâ€ <scp>d</scp> â€aspartate receptor encephalitis. Brain and Behavior, 2021, 11, e2277.	1.0	4
492	Status Epilepticus in Patients with Anti-NMDAR Encephalitis Requiring Intensive Care: A Follow-Up Study. Neurocritical Care, 2021, , 1.	1.2	5
493	Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. Molecular Diagnosis and Therapy, 2021, 25, 563-576.	1.6	5
494	Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management. Frontiers in Neurology, 2021, 12, 673339.	1.1	40
495	Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review. Journal of Neuroimmunology, 2021, 356, 577586.	1.1	15
496	Research progress in teratomaâ€associated <scp>antiâ€Nâ€methylâ€D</scp> â€aspartate receptor encephalitis: The gynecological perspective. Journal of Obstetrics and Gynaecology Research, 2021, 47, 3749-3757.	0.6	6
497	Monoclonal Antibodies From Anti-NMDA Receptor Encephalitis Patient as a Tool to Study Autoimmune Seizures. Frontiers in Neuroscience, 2021, 15, 710650.	1.4	6
498	NMDA-receptor encephalitis in Denmark from 2009 to 2019: a national cohort study. Journal of Neurology, 2022, 269, 1618-1630.	1.8	15

#	Article	IF	CITATIONS
499	Autoimmune Encephalitis Resembling Dementia Syndromes. Neurology: Neuroimmunology and NeuroInflammation, $2021,8,.$	3.1	22
500	Status epilepticus suspected autoimmune: Neuronal surface antibodies and main clinical features. Epilepsia, 2021, 62, 2719-2731.	2.6	9
501	Atypical Association of Autoimmune Limbic Encephalitis with Anti-NMDA Receptor Antibodies in a Young Male Patient: Clinical, Imaging, and Neuropsychological Characteristics. Case Reports in Neurology, 2021, 13, 541-548.	0.3	0
502	Autoimmune encephalitis and seizures, cerebrospinal fluid, imaging, and EEG findings: a case series. Neurological Sciences, 2022, 43, 2669-2680.	0.9	5
503	Anti-N-methyl-D-aspartate Receptor Encephalitis as a Paraneoplastic Presentation of Mature Ovarian Teratoma. American Journal of Case Reports, 2021, 22, e933240.	0.3	1
504	Successful treatment with immunoadsorption therapy in four patients with severe and refractory anti―N â€methylâ€Dâ€aspartate receptor encephalitis. Journal of Clinical Apheresis, 2021, 36, 886-892.	0.7	2
505	A Story That Begins Too Soon: A case of a girl with untreated Anti–N-methyl-d-aspartate receptor encephalitis for fourteen years. Canadian Journal of Neurological Sciences, 2021, , 1-6.	0.3	0
506	Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes. Neuro-Oncology Advances, 2021, 3, vdab145.	0.4	3
507	Chronic presence of blood circulating anti-NMDAR1 autoantibodies impairs cognitive function in mice. PLoS ONE, 2021, 16, e0256972.	1.1	7
508	Protein A immunoadsorption for the treatment of refractory anti-N-methyl-d-aspartate receptor encephalitis: A single-center prospective study. Journal of the Neurological Sciences, 2021, 428, 117568.	0.3	3
509	Discerning the Role of Autoimmunity and Autoantibodies in Epilepsy. JAMA Neurology, 2021, 78, 1383.	4.5	14
510	Diagnostic utility of cerebrospinal fluid (CSF) findings in seizures and epilepsy with and without autoimmune-associated disease. Seizure: the Journal of the British Epilepsy Association, 2021, 91, 233-243.	0.9	8
511	Real-world experience of assessing antibodies against the N-methyl-D-aspartate receptor (NMDAR-lgG) in psychiatric patients. A retrospective single-centre study. Brain, Behavior, and Immunity, 2021, 98, 330-336.	2.0	8
512	Antibodies Contributing to Focal Epilepsy Signs and Symptoms Score. Annals of Neurology, 2021, 89, 698-710.	2.8	42
513	Therapeutic Plasma Exchange in the Critically Ill Patient: Technology and Indications. Advances in Chronic Kidney Disease, 2021, 28, 59-73.	0.6	8
514	A Retrospective Study of Patients with GABABR Encephalitis: Therapy, Disease Activity and Prognostic Factors. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 99-110.	1.0	9
515	Autoimmune movement disorders., 2021,, 550-559.e4.		1
518	A Shared Diagnostic Stewardship Approach toward Improving Autoimmune Encephalopathy Send-out Testing Utilization. journal of applied laboratory medicine, The, 2021, 6, 387-396.	0.6	2

#	Article	IF	CITATIONS
520	Autoimmune seizures and epilepsy. Journal of Clinical Investigation, 2019, 129, 926-940.	3.9	152
521	Autoimmune Neurology of the Central Nervous System. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 627-653.	0.4	13
522	Paraneoplastic Disorders. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 1653-1679.	0.4	18
523	Comparison of Diagnostic Accuracy of Microscopy and Flow Cytometry in Evaluating N-Methyl-D-Aspartate Receptor Antibodies in Serum Using a Live Cell-Based Assay. PLoS ONE, 2015, 10, e0122037.	1.1	27
524	Increased serum anti-N-methyl-D-aspartate receptor antibody immunofluorescence in psychiatric patients with past catatonia. PLoS ONE, 2017, 12, e0187156.	1.1	10
525	Adult-onset temporal lobe epilepsy suspicious for autoimmune pathogenesis: Autoantibody prevalence and clinical correlates. PLoS ONE, 2020, 15, e0241289.	1.1	8
526	Autoimmune Encephalitis: Current Knowledge on Subtypes, Disease Mechanisms and Treatment. CNS and Neurological Disorders - Drug Targets, 2020, 19, 584-598.	0.8	23
527	Anti-NMDA Receptor Encephalitis in a Patient with a History of Autism Spectrum Disorder. Adolescent Psychiatry (Hilversum, Netherlands), 2020, 10, 231-235.	0.1	1
528	Autoantibody-Mediated Encephalitis. Deutsches Ärzteblatt International, 2018, 115, 666-673.	0.6	24
529	Anti-N-methyl-D-aspartate Receptor Encephalitis: a Rare Complication of Ovarian Teratoma. Journal of Korean Medical Science, 2020, 35, e207.	1.1	5
530	Autoimmune encephalitis following haematopoietic stem cell transplant: a new clinical entity or a previously unrecognised one?. Translational Pediatrics, 2015, 4, 327-30.	0.5	1
531	Factors Affecting the Response to First-Line Treatments in Patients with Anti-N-Methyl-D-Aspartate		

#	Article	IF	Citations
538	Application of Multimodal EEG in AE. , 2022, , 275-286.		0
539	Comprehensive B-Cell Immune Repertoire Analysis of Anti-NMDAR Encephalitis and Anti-LGI1 Encephalitis. Frontiers in Immunology, 2021, 12, 717598.	2.2	3
540	Autoimmunerkrankungen., 2015,, 577-607.		0
541	Paraneoplastic Neurological Syndromes. , 2015, , 353-385.		О
543	"The more we know― Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, .	3.1	0
545	Autoimmune Encephalitis: Clinical Features, Pathophysiology, and Treatment. , 2017, , 175-186.		O
546	Cortical Aphasia and Apraxia as Main Clinical Presentation of Anti-NMDAR Encephalitis Relapse with a Positive CSF PCR for Cytomegalovirus. Neuropsychiatry, 2017, 07, .	0.4	0
547	Six autoantibodies associated with autoimmune encephalitis are not detectable in the cerebrospinal fluid of suicide attempters. PLoS ONE, 2017, 12, e0176358.	1.1	4
548	Corticosteroid Treatment in Autoimmune Encephalitis. Journal of Neurocritical Care, 2017, 10, 60-68.	0.4	2
549	Autoantikörper gegen Glutamat-Rezeptoren Typ NMDA. , 2018, , 1-2.		0
551	When the Body Attacks the Brain. , 2019, , 213-226.		0
552	Paraneoplastic Teratoma-associated Anti-N-Methyl-D-Aspartate Receptor Encephalitis: The First Published Report from Saudi Arabia. Cureus, 2018, 10, e3527.	0.2	1
553	Encéphalite à anticorps anti-NMDAR révélée par une symptomatologie psychiatrique. Annales Francaises De Medecine D'Urgence, 2019, 9, 120-121.	0.0	0
554	Paraneoplastic Neurological Syndromes. Contemporary Clinical Neuroscience, 2019, , 439-485.	0.3	3
555	Autoimmune Astrocytopathy. Contemporary Clinical Neuroscience, 2019, , 329-355.	0.3	0
556	Glutamate Receptor Antibodies in Autoimmune Central Nervous System Disease: Basic Mechanisms, Clinical Features, and Antibody Detection. Methods in Molecular Biology, 2019, 1941, 225-255.	0.4	4
558	Autoimmune Limbic Encephalitis. Contemporary Clinical Neuroscience, 2019, , 567-597.	0.3	0
559	Autoantikörper gegen Glutamat-Rezeptoren Typ NMDA. Springer Reference Medizin, 2019, , 285-286.	0.0	0

#	Article	IF	CITATIONS
560	Clinical Reasoning: A 23-Year-Old Female Presenting Abnormal Behavior, Seizure, and Altered Mentality. Journal of the Korean Neurological Association, 2019, 37, 109-116.	0.0	0
561	Anti-NMDAR autoimmune encephalitis in children and herpes simplex virus-1. Rossiyskiy Vestnik Perinatologii I Pediatrii, 2019, 64, 17-27.	0.1	2
562	Childhood Onset of Anti-N-Methyl-D-Aspartate Receptor Encephalitis Without Teratoma Masquerading as a Psychotic Disorder. Soa¡\$ceongso'nyeon Jeongsin Yihag, 2019, 30, 127-131.	0.3	0
563	Autoimmune-Mediated Encephalitis: Main Clinical Syndromes and Antibody Effects. Journal of the Nihon University Medical Association, 2019, 78, 319-324.	0.0	O
564	Ovarian Immature Teratoma Complicated with Anti-NMDA Receptor Encephalitis: A Case Report. Advances in Clinical Medicine, 2020, 10, 1011-1016.	0.0	0
565	Recommandations Formalisées d'Experts SRLF/SFMU : Prise en charge des états de mal épileptiques en préhospitalier, en structure d'urgence et en réanimation dans les 48 premières heures (A l'exclusion)	Ђ <b>.</b> бТQq1	<b>≥</b> 0.78431
566	Initial cerebrospinal fluid-restricted oligoclonal bands associate with anti-N-methyl-D-aspartate receptor encephalitis severity: a pilot study. Encephalitis, 2020, 1, 7-13.	0.3	0
568	Paraneoplastische Syndrome und antikĶrpervermittelte Enzephalitiden. , 2020, , 273-293.		1
570	Not Your Average Seizure: A Case of N-Methyl-D-Aspartate Receptor Encephalitis and Review of Literature. Cureus, 2020, 12, e9068.	0.2	2
571	The association of herpes simplex type 1 encephalitis and anti –N methyl D aspartate receptor antibody encephalitis in a case. Anadolu GÃ⅓ncel Tıp Dergisi, 2020, 2, 152-155.	0.0	O
573	More than just anti-NMDAR: the many facets of autoimmune encephalitis. BJPsych Bulletin, 2022, 46, 197-201.	0.7	2
574	The clinical features, treatment and outcomes of 33 children from Northwestern China with Anti-N-methyl-D-aspartate receptor encephalitis. Neurological Research, 2021, , 1-10.	0.6	1
575	Anti-NMDAR encephalitis presenting after immature teratoma resection. BMJ Case Reports, 2021, 14, e244637.	0.2	2
576	Antibody Therapies in Autoimmune Encephalitis. Neurotherapeutics, 2022, 19, 823-831.	2.1	18
577	Anti-NMDAR Encephalitis., 2022,, 210-254.		0
578	Pathogenesis and Disease Mechanisms in Neuronal Antibody-Mediated Encephalitis. , 2022, , 42-106.		1
579	Deconstructing Hashimoto Encephalopathy. , 2022, , 460-475.		0
580	Case Analysis and Literature Review of Thirteen Patients with Autoimmune Encephalitis. Disease Markers, 2022, 2022, 1-7.	0.6	2

#	ARTICLE	IF	CITATIONS
581	Disturbance of Gut Bacteria and Metabolites Are Associated with Disease Severity and Predict Outcome of NMDAR Encephalitis: A Prospective Case–Control Study. Frontiers in Immunology, 2021, 12, 791780.	2.2	4
582	Clinical Features and Therapeutic Effects of Anti-leucine-rich Glioma Inactivated 1 Encephalitis: A Systematic Review. Frontiers in Neurology, 2021, 12, 791014.	1.1	11
583	Case 1-2022: A 67-Year-Old Man with Motor Neuron Disease and Odd Behaviors during Sleep. New England Journal of Medicine, 2022, 386, 173-180.	13.9	4
584	Importance, Definitions, History, Classification, and Frequency of the Autoimmune Encephalitides., 2022, , 1-18.		1
585	Diagnostic approach and treatment regimens in adult patients suffering from antibody-mediated or paraneoplastic encephalitis. Current Pharmaceutical Design, 2022, 28, .	0.9	1
586	Autoimmune Psychosis., 2022,, 503-526.		1
587	The blood–CSF–brain route of neurological disease: The indirect pathway into the brain. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	9
588	Anti-NMDA Receptor Encephalitis Masquerades as Psychosis: A Case Report. Journal of Psychiatric Practice, 2022, 28, 72-77.	0.3	O
589	Dopamine-2 receptor antibody encephalitis presenting as pure tongue-biting in a tourette syndrome patient: a case report. BMC Psychiatry, 2022, 22, 47.	1.1	4
590	Psychiatric Manifestations of Autoimmune Encephalitis. , 2022, , 527-544.		1
591	Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1/Caspr2 encephalitis: a prospective cohort study in Western China. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642110732.	1.5	15
592	Contemporary advances in anti-NMDAR antibody (Ab)-mediated encephalitis. Autoimmunity Reviews, 2022, 21, 103057.	2.5	13
593	Research progress of antiâ€Î³â€aminobutyric acid B receptor encephalitis and a case report of paraneoplastic associated encephalitis and treatment analysis. , 2022, 8, 15-22.		0
594	Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis. Neurology, 2022, 98, .	1.5	25
595	The prognosis of lateâ€onset antiâ€Nâ€methylâ€Dâ€aspartate receptor encephalitis in China. Acta Neurologica Scandinavica, 2022, 145, 449-455.	1.0	2
596	Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations. Mayo Clinic Proceedings, 2022, 97, 547-559.	1.4	29
599	Persistent Fever After Treatment of HSV Encephalitis – Is This Expected?. American Journal of Medicine, 2022, , .	0.6	0
600	The Antibody Assay in Suspected Autoimmune Encephalitis From Positive Rate to Test Strategies. Frontiers in Immunology, 2022, 13, 803854.	2.2	3

#	Article	IF	CITATIONS
601	Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease. Frontiers in Neurology, 2022, 13, 866824.	1.1	16
602	Paraneoplastic syndromes review: The great forgotten ones. Critical Reviews in Oncology/Hematology, 2022, 174, 103676.	2.0	7
603	Detection and significance of neuronal autoantibodies in patients with meningoencephalitis in Vientiane, Lao PDR. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, $116$ , $959-965$ .	0.7	1
604	Autoimmune-Associated Seizures. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 363-398.	0.4	4
605	Autoimmune Encephalitis. Pediatrics in Review, 2022, 43, 198-211.	0.2	5
606	Inconsistency of Antibody Testing in a Patient with Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Asian Journal of Psychiatry, 2022, 72, 103124.	0.9	0
607	Autoimmune Encephalitis: Distinguishing Features and Specific Therapies. Critical Care Clinics, 2022, 38, 393-412.	1.0	1
608	Diagnostic Difficulties and Treatment Challenges of a Young Patient With Severe Acute Psychosis and Complete Recovery. Cureus, 2022, 14, e23744.	0.2	0
610	CSF-Neurofilament Light Chain Levels in NMDAR and LGI1 Encephalitis: A National Cohort Study. Frontiers in Immunology, 2021, 12, 719432.	2.2	11
611	Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. International Journal of Molecular Sciences, 2021, 22, 13127.	1.8	20
612	Relapse factors of patients of antiâ€Nâ€methylâ€Dâ€aspartate receptor encephalitis. Acta Neurologica Scandinavica, 2022, 145, 434-441.	1.0	6
613	Therapeutic apheresis in the complex pathogenetic therapy of anti-NMDA encephalitis associated with ovarian teratoma at a late stage of the disease. Nervno-Myshechnye Bolezni, 2021, 11, 34-47.	0.2	1
614	Validation of the Clinical Assessment Scale in Autoimmune Encephalitis in Chinese Patients. Frontiers in Immunology, 2021, 12, 796965.	2.2	13
615	Allosteric Modulation of NMDARs Reverses Patients' Autoantibody Effects in Mice. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	10
617	Clinical Relevance of Cerebrospinal Fluid Antibody Titers in Anti-N-Methyl-d-Aspartate Receptor Encephalitis. Brain Sciences, 2022, 12, 4.	1.1	4
618	Anti-NMDAR Encephalitis in the Netherlands, Focusing on Late-Onset Patients and Antibody Test Accuracy. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	19
619	Autoimmune epilepsy. Epilepsy and Paroxysmal Conditions, 2022, 14, 74-90.	0.2	2
621	Influential Factors, Treatment and Prognosis of Autoimmune Encephalitis Patients With Poor Response to Short-Term First-Line Treatment. Frontiers in Neurology, 2022, 13, 861988.	1.1	1

#	Article	IF	Citations
622	Long-Term Prognosis of Patients With Anti-N-Methyl-D-Aspartate Receptor Encephalitis Who Underwent Teratoma Removal: An Observational Study. Frontiers in Neurology, 2022, 13, 874867.	1.1	1
631	Clinical characteristics of antiNmethylaspartate receptor encephalitis in children. Journal of Central South University (Medical Sciences), 2020, 45, 47-54.	0.1	3
632	Paraneoplastic Neurological Syndromes: Transitioning Between the Old and the New. Current Oncology Reports, 2022, 24, 1237-1249.	1.8	2
633	Case Report: Cotard's Syndrome in Anti-N-methyl D-aspartate (NMDA) Receptor (Anti-NMDAR) Encephalitis. Frontiers in Psychiatry, 2022, 13, .	1.3	3
634	Seronegative autoimmune encephalitis: clinical characteristics and factors associated with outcomes. Brain, 2022, 145, 3509-3521.	3.7	32
635	Autoimmune Encephalitis in Children. Pediatric Neurology, 2022, 132, 56-66.	1.0	8
636	Paediatric anti-NMDA-receptor encephalitis with ovarian teratoma. Journal of Pediatric Surgery Case Reports, 2022, , 102318.	0.1	0
637	Paraneoplastic limbic encephalitis following treatment with single-agent pembrolizumab for advanced gastroesophageal adenocarcinoma. BMJ Case Reports, 2022, 15, e247676.	0.2	2
638	Diagnosis and Clinical Features in Autoimmune-Mediated Movement Disorders. Journal of Movement Disorders, 2022, 15, 95-105.	0.7	0
639	Late relapse of anti-N-methyl-d-aspartate receptor encephalitis with amusia and transiently reduced uptake in 123I-iomazenil single-photon emission computed tomography. Brain and Development, 2022, 44, 558-561.	0.6	1
640	Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B). Journal of Neurology, 2022, 269, 5521-5530.	1.8	2
641	Life after autoantibody-mediated encephalitis: optimizing follow-up and management in recovering patients. Current Opinion in Neurology, 2022, 35, 415-422.	1.8	3
642	Autoimmunity to Glutamate Receptor Channels. Neurology and Clinical Neuroscience, 0, , .	0.2	0
643	Relapses of Anti-NMDAR, Anti-GABABR and Anti-LGI1 Encephalitis: A Retrospective Cohort Study. Frontiers in Immunology, 0, 13, .	2.2	10
644	Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Neuropsychiatric and Multidisciplinary Approach to a Patient Not Responding to First-Line Treatment. Cureus, 2022, , .	0.2	0
645	Rapidly Progressive Dementia. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 901-936.	0.4	8
646	Immunotherapy in autoimmune encephalitis. Current Opinion in Neurology, 2022, 35, 399-414.	1.8	11
647	Refractory Anti-NMDA Receptor Encephalitis in Early Pregnancy. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	2

#	Article	IF	CITATIONS
648	Disease progression and brain atrophy in <scp>NMDAR</scp> encephalitis: Associated factor & amp; clinical implication. Annals of Clinical and Translational Neurology, 2022, 9, 912-924.	1.7	4
649	Autoantibody Encephalitis: Presentation, Diagnosis, and Management. Journal of Clinical Neurology		

#	Article	IF	CITATIONS
668	Molecular disease mechanisms of human antineuronal monoclonal autoantibodies. Trends in Molecular Medicine, 2023, 29, 20-34.	3.5	11
669	Multi-proteomic Analysis Revealed Distinct Protein Profiles in Cerebrospinal Fluid of Patients Between Anti-NMDAR Encephalitis NORSE and Cryptogenic NORSE. Molecular Neurobiology, 2023, 60, 98-115.	1.9	7
670	Meningo-cortical manifestations of myelin oligodendrocyte glycoprotein antibody-associated disease: Review of a novel clinico-radiographic spectrum. Frontiers in Neurology, 0, 13, .	1.1	9
671	Detection of paraneoplastic antibodies and their significance in paraneoplastic neurologic syndromes: a narrative review. Annals of Translational Medicine, 2023, 11, 283-283.	0.7	3
672	Atypical psychiatric presentation of relapsing anti-N-methyl-D-aspartate receptor encephalitis in childhood. Clinical Child Psychology and Psychiatry, 2023, 28, 1333-1340.	0.8	1
673	The study of neural antibodies in neurology: A practical summary. Frontiers in Immunology, 0, 13, .	2.2	2
674	Single-cell transcriptomics reveals cell type $\hat{a} \in ``specific immune regulation associated with anti-NMDA receptor encephalitis in humans. Frontiers in Immunology, 0, 13, .$	2.2	4
675	The diagnosis of anti-LGI1 encephalitis varies with the type of immunodetection assay and sample examined. Frontiers in Immunology, $0,13,.$	2.2	2
676	Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF. Neurology, 2023, 100, .	1.5	22
677	Child with Suspected Autoimmune Encephalitis. , 2022, , 625-638.		0
678	Anti-N-Methyl-D-Aspartate receptor encephalitis in pediatrics: A review of clinical manifestations, treatment, and prognosis. Mustansiriya Medical Journal, 2022, 21, 96.	0.1	0
679	Neuronal surface antigen-specific immunostaining pattern on a rat brain immunohistochemistry in autoimmune encephalitis. Frontiers in Immunology, $0,13,.$	2.2	3
680	Case report: Anti-N-methyl-D-aspartate receptor antibody-associated autoimmunity triggered by primary central nervous system B-cell lymphoma. Frontiers in Neurology, 0, 13, .	1.1	2
681	Anti-NMDA Receptor Autoimmune Encephalitis: Diagnosis and Management Strategies. International Journal of General Medicine, 0, Volume 16, 7-21.	0.8	16
682	Anti-leucine-rich glioma inactivated protein 1 encephalitis with sleep disturbance as the first symptom: A case report and review of literature. World Journal of Clinical Cases, 0, 11, 408-416.	0.3	1
683	A narrative review of identifying the culprit antibody in neuroimmune diseases: concept and clinical significance. Annals of Translational Medicine, 2023, .	0.7	1
684	Early predictors of new-onset immune-related seizures: a preliminary study. BMC Neurology, 2022, 22, .	0.8	1
685	Cytokine/chemokine levels in the CSF and serum of anti-NMDAR encephalitis: A systematic review and meta-analysis. Frontiers in Immunology, $0,13,.$	2.2	4

#	Article	IF	CITATIONS
686	Challenging Cases in Neuroimmunology. Seminars in Neurology, 2022, 42, 695-707.	0.5	1
687	DPPX antibody-associated encephalitis: A short report on a Chinese patient. Neuroimmunology Reports, 2023, 3, 100171.	0.2	0
688	Brain blood vessel autoantibodies in patients with NMDA and GABAA receptor encephalitis: identification of unconventional Myosin-X as target antigen. Frontiers in Cellular Neuroscience, 0, 17, .	1.8	2
689	Overlapping anti-NMDAR encephalitis and multiple sclerosis: A case report and literature review. Frontiers in Immunology, $0,14,.$	2.2	5
690	The brain reacting to COVID-19: analysis of the cerebrospinal fluid proteome, RNA and inflammation. Journal of Neuroinflammation, 2023, 20, .	3.1	13
691	Paraneoplastic Neurologic Disorders. Current Neurology and Neuroscience Reports, 2023, 23, 67-82.	2.0	6
692	Limbic Encephalitis and Autoimmune Encephalitides: Pathophysiology, Classification, Clinical Presentation, and Treatment. World Journal of Neuroscience, 2023, 13, 39-66.	0.1	0
693	Approach to New-Onset Psychosis in Pediatrics: A Review of Current Practice and an Interdisciplinary Consensus-Driven Clinical Pathway at a Single-Center Institution. Journal of Child Neurology, 2023, 38, 216-222.	0.7	0
694	A young adult with first-episode psychosis: when to consider anti– <i>N</i> -methyl-D-aspartate receptor encephalitis. Cmaj, 2023, 195, E330-E332.	0.9	0
696	Characterization of neuroinflammation pattern in anti-LGI1 encephalitis based on TSPO PET and symptom clustering analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 2394-2408.	3.3	2
697	Predictive Value of Serum Neurofilament Light Chain Levels in Anti-NMDA Receptor Encephalitis. Neurology, 2023, 100, .	1.5	3
698	Can Neurofilament Light Chain Be Utilized as a Biomarker of Disease Severity, Activity, and Outcomes in Anti-NMDA Receptor Encephalitis?. Neurology, 2023, 100, 991-992.	1.5	0
699	Autoimmune encephalitis: Epidemiology, pathophysiology and clinical spectrum (part 2). South African Medical Journal, 0, , .	0.2	0
700	Nonparaneoplastic anti-NMDA receptor encephalitis in an adolescent girl: a case report. Annals of Medicine and Surgery, 2023, 85, 2010-2013.	0.5	1
701	Anti-mGluR1 encephalitis: Case illustration and systematic review. Frontiers in Neurology, 0, 14, .	1.1	4
702	Persistent psychosis associated with extreme delta brush in anti-NMDA receptor encephalitis: a case report. BMC Psychiatry, 2023, 23, .	1.1	0
720	Controversies in immunotherapy for anti-NMDA receptor encephalitis: a scoping review with a proposal of operational definitions. Neurological Sciences, 0, , .	0.9	0
739	Case Report: Anti-mGluR5 antibody-negative Ophelia syndrome with failed lymph node biopsy due to steroid therapy. Frontiers in Immunology, 0, 14, .	2.2	0

#	ARTICLE	IF	CITATIONS
743	Neurobiology of Neuroimmune Encephalitic Disorders. , 2023, , 1-39.		0
755	Autoimmune and paraneoplastic seizures. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 151-172.	1.0	O